FDA approves Foundation Medicine’s genomic profiling test for all solid tumors; CMS proposes coverage

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has approved the FoundationOne CDx, the first breakthrough-designated, next generation sequencing-based in vitro diagnostic test that can detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Matthew Bin Han Ong
Senior Editor

YOU MAY BE INTERESTED IN

People of African ancestry (Black/African American) have some of the worst cancer incidence and greatest mortality, compared to white and other racial and ethnic populations in the U.S. On average, Black persons are 1.5 times more likely to have cancer and >2X more likely to die from cancer compared to whites. xxx:more
Matthew Bin Han Ong
Senior Editor

Login